Paclitaxel-loaded biodegradable nanoparticles developed by direct dialysis and electrodydrodynamic atomization methods

AIChE Annual Meeting, Conference Proceedings

Volumn , Issue , 2004, Pages 2193-2202

  Xie, Jingwei ^a   Wang, Chi Hwa ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SINGAPORE MIT ALLIANCE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXICITY; DRUG DELIVERY; EMULSIFERS; POLYMERIC NANOPARTICLES;

BIODEGRADATION; DIALYSIS; DRUG PRODUCTS; EMULSIONS; EVAPORATION; FABRICATION; ORGANIC POLYMERS; POLYVINYL ACETATES; SCANNING ELECTRON MICROSCOPY; SOLVENTS;

NANOSTRUCTURED MATERIALS;

EID: 22544477569     PISSN: None     EISSN: None     Source Type: Conference Proceeding    
DOI: None     Document Type: Conference Paper

References (25)

1. DESJARDINS, M. and GRIFFITHS, G. 2003. Phagocytosis: latex leads the way. Current opinion in cell biology. 15, 498-503.
2. FELLNER, S., BAUER, B., MILLER, D. S. et al., 2002. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. Journal of Clinical Investigation. 110(9), 1309-1318.
3. FENG, S. S., CHIEN, S. 2003. Chemotherapeutic engineering: Application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chemical Engineering Science. 58, 4087-4114.
4. FENG, S. S., HUANG, G. F. 2001. Effect of emulsifiers on the controlled release of paclitaxel from nanospheres of biodegradable polymers. J. Contr. Rel. 71, 53-69.
5. FONSECA, C., SIMOES, S., CASPAR, R. 2002. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J. Contr. Rel. 83, 273-286.
6. GAGANDEEP, S., NOVIKOFF, P.M., OTT, M., GUPTA, S. 1999. Paclitaxel shows cytotoxic activity in human hepatocellular carcinoma cell lines. Cancer Research. 136, 109-118.
7. JEONG, Y. I., CHO, C. S., KIM, S. H., KO, K. S., KIM, S. I., SHIM, Y. H., NAH, J. W. 2001. Preparation of poly (DL-lactide -co-glycolide) nanoparticles without surfactant. J. Appl. Poly. Sci. 80, 2228-2236.
8. JEONG, Y. I., CHEON, J. B., KIM, S. H., NAH, J. W., LEE, Y. M., SUNG, Y. K., AKAIKE, T., CHO, C. S. 1998. Clonazepam release from core-shell type nanoparticles in vitro. J. Contr. Rel. 51, 169-178.
9. JEONG, Y. I., SHIM, Y. H., CHOI, C. Y., JANG, M. K., SHIN, G. M., NAH, J. W. 2003. Surfactant-free nanoparticles of poly (DL-lactide-co-glycolide) prepared with poly (L-lactide)/poly(ethylene glycol). J. Appl. Poly. Sci.89(4), 1116-1123.
10. JORDAN, M. A., TOSO, R.J., THROWER, D. 1993. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc. Natl. Acad. Sci. USA. 90, 9552-9556.
11. JORDAN, M. A. and WILSON, L. 2004. Microtubules as a target for anticancer drugs, Nature Reviews Cancer. 4, 253-265.
12. LANDRY, F. B., BAZILE, D. V., SPENLEHAUER, G., VEILLARD, M., KREUTER, J. 1995. Release of the fluorescent marker Prodan® from poly (D,L-lactic acid) nanoparticles coated with albumin or polyvinyl alcohol in model digestive fluids (USP XXII). J. Contr. Rel. 44, 227-236.
13. LAVELLE, E. C., SHARIF, S., THOMAS, N. W., HOLLAND, J., DAVIS, S. S. 1995. The importance of gastrointestinal uptake of particles in the design of oral delivery systems. Adv. Drug Deliv. Rev. 18, 5-22.
14. LIEBMANN, J. E., COOK, J. A., LIPSCHULTZ, C., TEAGUE, D., FISHER, J., MITCHELL, J. B. 1993. Cytotoxic studies of paclitaxel (Taxol®) in human tumour cell lines. Br. J. Cancer. 68, 1104-1109.
15. LOCKMAN, P. R., MUMPER, R. J., KHAN, M. A. 2002. Nanoparticle technology for drug delivery across the blood brain barrier. Drug Development and Industrial Pharmacy, 28(1), 1-13.
16. MILLER, G. 2002. Drug targeting: breaking down barrier. Science. 297, 1116-1118.
17. MU, L., FENG, S. S. 2002. Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol®). J. Contr. Rel. 80, 129-144.
18. NOSKE, W., LENTZEN, H., LANGE, K., KELLER, K. 1982. Phagocytotic activity of glial cells in culture. Experimental Cell Research. 142, 437-445.
19. RAYMOND, E., HANAUSKE, A., FAIVRE, S. et al. 1997. Effects of prolonged versus short-term exposure paclitaxel (Taxol®) on human tumor colony-forming units. Anti-Cancer Drugs. 8(4), 379-385.).
20. ROWINSKY, E.K., WRIGHT, M., MONSARRAT, B., LESSER, G.J., DONEHOWER, R.C. 1993. Taxol: Pharmacology, metabolism and clinical implications. Cancer Surveys. 17, 283-301.
21. SAHOO, S. K., PANYAM, J., PRABHA, S., LABHASETWAR, V. 2002. Residual polyvinyl alcohol associated with poly (D, L- Lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J. Contr. Rel. 82, 105-114
22. SINGLA, A. K., GARG, A., AGGARWAL, D. 2002. Paclitaxel and its formulations. International Journal of Pharmaceutics. 235, 179-192.
23. WATTS, A. and MARSH, M. 1992. Endocytosis: what goes in and how?. Journal of Cell Science. 103, 1-8.
24. XU, K. L., LUDUENA, R. F. 2002. Characterization of Nuclear β□-Tubulin in Tumor cells: A possible novel target for Taxol. Cell motility and the Cytoskeleton 53, 39-52.
25. ZIMMER, C., WEISSLEDER, R., POSS, K., BOGDANOVA, A., WRIGHT, S.C., ENOCHS, W. S. 1995. MR imaging of phagocytosis in experimental gliomas. Radiology. 197, 533-538.